Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
暂无分享,去创建一个
Deepak L. Bhatt | A. Bagai | S. Mehta | J. Eikelboom | R. Vijayaraghavan | J. Udell | A. Cheema | J. Tanguay | G. Mancini | E. Cohen | J. Niznick | S. Verma
[1] Marc P. Bonaca,et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. , 2015, European heart journal.
[2] Seung‐Jung Park,et al. Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. , 2015, Journal of the American College of Cardiology.
[3] Giuseppe Biondi-Zoccai,et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials , 2015, The Lancet.
[4] S. Windecker,et al. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. , 2015, Journal of the American College of Cardiology.
[5] Walter Desmet,et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. , 2015, European heart journal.
[6] Marc P. Bonaca,et al. Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.
[7] Braunwald,et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.
[8] A. Jaffe,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[9] Antonio Colombo,et al. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. , 2014, Journal of the American College of Cardiology.
[10] Helmut Baumgartner,et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[11] Silvia G Priori,et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.
[12] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[13] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[14] Deepak L. Bhatt,et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. , 2007, Journal of the American College of Cardiology.
[15] S. Yusuf,et al. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.
[16] Patrice Cacoub,et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.
[17] Eric J Topol,et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[18] Helmut Baumgartner,et al. ESC / EACTS Guidelines on myocardial revascularization , 2014 .
[19] Deepak L. Bhatt,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.
[20] P. R. R. Ecurrent,et al. EFFECTS OF CLOPIDOGREL IN ADDITION TO ASPIRIN IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION , 2001 .
[21] Caroline A Milton,et al. For personal use. Only reproduce with permission from The Lancet Publishing Group. Late cardiopulmonary complication of ventriculo-atrial shunt , 2001 .